Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply
Talha Munir1, David A Cairns2, Peter Hillmen2
1Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom.
The New England Journal of Medicine
|December 3, 2025
Summary
No abstract available in PubMed .
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.6K
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
537
